BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morand EF, Mosca M. Treat to target, remission and low disease activity in SLE. Best Practice & Research Clinical Rheumatology 2017;31:342-50. [DOI: 10.1016/j.berh.2017.09.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. Rheumatol Ther 2020;7:433-46. [PMID: 32488652 DOI: 10.1007/s40744-020-00212-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
2 Gao D, Hao Y, Fan Y, Ji L, Zhang Z. Predicting lupus low disease activity state and remission in SLE: novel insights. Expert Rev Clin Immunol 2021;:1-7. [PMID: 34392757 DOI: 10.1080/1744666X.2021.1968297] [Reference Citation Analysis]
3 Andrade SO, Julio PR, Nunes de Paula Ferreira D, Appenzeller S. Predicting lupus flares: epidemiological and disease related risk factors. Expert Rev Clin Immunol 2021;17:143-53. [PMID: 33393397 DOI: 10.1080/1744666X.2020.1865156] [Reference Citation Analysis]
4 He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, Liu J, Zhang X, Zhang X, Jin Y, Wang Y, Zhang S, Zhu L, Jacob A, Jia R, You X, Li X, Li C, Zhou Y, Yang Y, Ye H, Liu Y, Su Y, Shen N, Alexander J, Guo J, Ambrus J, Lin X, Yu D, Sun X, Li Z. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2020;79:141-9. [PMID: 31537547 DOI: 10.1136/annrheumdis-2019-215396] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 22.0] [Reference Citation Analysis]
5 Floris A, Piga M, Perra D, Chessa E, Congia M, Mathieu A, Cauli A. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage. Arthritis Care Res (Hoboken) 2020;72:1794-9. [PMID: 31600023 DOI: 10.1002/acr.24086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hruskova Z, Tesar V. Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. Expert Opin Biol Ther 2018;18:989-96. [PMID: 30040494 DOI: 10.1080/14712598.2018.1504918] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
7 Cho J, Liang S, Lim SHH, Lateef A, Tay SH, Mak A. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio reflect disease activity and flares in patients with systemic lupus erythematosus - A prospective study. Joint Bone Spine 2022;89:105342. [PMID: 35032639 DOI: 10.1016/j.jbspin.2022.105342] [Reference Citation Analysis]
8 Doi H, Ohmura K, Tabuchi Y, Hashimoto M, Takase Y, Inaba R, Kozuki T, Iwasaki T, Taniguchi M, Kitagori K, Akizuki S, Murakami K, Nakashima R, Yoshifuji H, Yamamoto W, Tanaka M, Akio M. Validation and verification of the Japanese version of the systemic lupus erythematosus symptom checklist for patient quality of life. Lupus 2021;30:1108-15. [PMID: 33779381 DOI: 10.1177/09612033211005026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nikolopoulos DS, Kostopoulou M, Pieta A, Flouda S, Chavatza K, Banos A, Boletis J, Katsimbri P, Boumpas DT, Fanouriakis A. Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease. Lupus Sci Med 2020;7:e000394. [PMID: 32601172 DOI: 10.1136/lupus-2020-000394] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Xu F, Jin L, Jin Y, Nie Z, Zheng H. Long noncoding RNAs in autoimmune diseases. J Biomed Mater Res A 2019;107:468-75. [PMID: 30478988 DOI: 10.1002/jbm.a.36562] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
11 Cho J, Lahiri M, Teoh LK, Dhanasekaran P, Cheung PP, Lateef A. Predicting flares in patients with stable systemic lupus erythematosus. Semin Arthritis Rheum 2019;49:91-7. [PMID: 30660381 DOI: 10.1016/j.semarthrit.2019.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Gergianaki I, Bertsias G. Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. Front Med (Lausanne) 2018;5:161. [PMID: 29896474 DOI: 10.3389/fmed.2018.00161] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
13 Ford JA, Solomon DH. Challenges in Implementing Treat-to-Target Strategies in Rheumatology. Rheum Dis Clin North Am 2019;45:101-12. [PMID: 30447739 DOI: 10.1016/j.rdc.2018.09.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
14 Li Y, Wang H, Zhang Z, Tang C, Zhou X, Mohan C, Wu T. Identification of polo-like kinase 1 as a therapeutic target in murine lupus. Clin Transl Immunology 2022;11:e1362. [PMID: 35024139 DOI: 10.1002/cti2.1362] [Reference Citation Analysis]
15 Pearce FA, Rutter M, Sandhu R, Batten RL, Garner R, Little J, Narayan N, Sharp CA, Bruce IN, Erb N, Griffiths B, Guest H, Macphie E, Packham J, Hiley C, Obrenovic K, Rivett A, Gordon C, Lanyon PC. BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. Rheumatology (Oxford) 2021;60:1480-90. [PMID: 33291150 DOI: 10.1093/rheumatology/keaa759] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Takeshima Y, Iwasaki Y, Nakano M, Narushima Y, Ota M, Nagafuchi Y, Sumitomo S, Okamura T, Elkon K, Ishigaki K, Suzuki A, Kochi Y, Yamamoto K, Fujio K. Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus. Ann Rheum Dis 2022:annrheumdis-2021-221464. [PMID: 35236659 DOI: 10.1136/annrheumdis-2021-221464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Rua-Figueroa Fernández de Larrinoa Í, Lozano MJC, Fernández-Cid CM, Cobo T, Salman Monte TC, Freire González M, Hidalgo Bermejo FJ, Román Gutiérrez CS, Cortés-Hernández J. Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment. Expert Opin Biol Ther 2022;:1-9. [PMID: 35815355 DOI: 10.1080/14712598.2022.2096406] [Reference Citation Analysis]